Cubicin Endocarditis Trial Shows Improved Renal Safety Over Vancomycin
This article was originally published in Pharmaceutical Approvals Monthly
Pivotal data for Cubist's Cubicin treatment of endocarditis/bacteremia show comparable efficacy to standard care with superior renal safety, the firm reported Dec. 16
You may also be interested in...
Cubist plans to request a priority review for an sNDA it will submit by year-end for use of its Cubicin antibiotic for endocarditis and bacteremia
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011